Lenacapavir: FDA Approves New HIV PrEP Option
News Context
At a glance
The FDA’s approval of lenacapavir, a groundbreaking twice-yearly injectable, signals a new era for HIV prevention. This long-acting PrEP option provides a crucial advancement for those seeking to protect themselves against HIV, offering a meaningful alternative to daily oral medications.This progress promises to transform the landscape of HIV prevention, perhaps increasing accessibility and adherence. News Directory 3 brings you the latest on this pivotal moment in public health, detailing the benefits and implications of this innovative approach. Learn about the impact on patient care and broader community health. Discover what’s next.